/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. BioTech Nation ... with Dr. Moira Gunn
  2. Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals
Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals

BioTech Nation ... with Dr. Moira Gunn · Oct 13, 2026

LB Pharma is optimizing European antipsychotic amisulpride into a lower-dose, once-daily US treatment for schizophrenia and depression.

Optimizing Blood-Brain Barrier Penetration Unlocks Long-Acting Injectables for High-Dose Neuropsychiatric Drugs

Amisulpride requires high doses because it struggles to cross into the brain, making long-acting injectables unviable. By engineering the molecule to penetrate the brain more readily, LB Pharmaceuticals reduced the required dose from 400 milligrams to 50 milligrams. This reduction enables both once-daily oral dosing and monthly injectable formulation.

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals thumbnail

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals

BioTech Nation ... with Dr. Moira Gunn·a month ago

Dose-Dependent Dopamine Modulation Allows Benzamides to Address Both Psychosis and Depressive Symptoms

The benzamide chemical class offers a unique mechanism by suppressing dopamine or triggering its release based on dosage. LB Pharmaceuticals utilizes this dose-dependent trait to address excessive dopamine in schizophrenia as well as dopamine deficits in depressive disorders using a single molecular foundation.

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals thumbnail

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals

BioTech Nation ... with Dr. Moira Gunn·a month ago

Antipsychotic Tolerability Directly Determines Brain Health by Preventing Discontinuation-Induced Relapse

Roughly 74 percent of schizophrenia patients discontinue medication within 18 months, driven by intolerable side effects or ineffective treatment. Each resulting psychotic relapse can cause irreparable brain harm and worsen cognitive function. Minimizing adverse effects is therefore a vital neuroprotective measure to maintain continuous adherence.

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals thumbnail

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals

BioTech Nation ... with Dr. Moira Gunn·a month ago

FDA Requires Full De Novo Clinical Programs Despite Decades of Foreign Generic Precedent

Despite amisulpride recording millions of annual prescriptions abroad with established safety, the FDA barred LB Pharmaceuticals from submitting foreign clinical data. The agency treats the modified drug as completely new, forcing developers to run a full domestic development program from scratch rather than relying on existing evidence.

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals thumbnail

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals

BioTech Nation ... with Dr. Moira Gunn·a month ago

Reformulating an Oral Drug into a Long-Acting Injectable Resets Clinical Development Cycles

Transitioning an oral therapy into a once-monthly injectable requires launching a completely separate clinical development program. Despite prior oral trials, the FDA requires full Phase 3 studies to independently establish safety and efficacy for the alternate formulation, resetting the regulatory timeline.

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals thumbnail

Improving a Drug for Managing Schizophrenia…Heather Turner, CEO, LB Pharmaceuticals

BioTech Nation ... with Dr. Moira Gunn·a month ago